索磷布韦/维帕他韦/利巴韦林联合治疗混合基因型HCV感染者1例报告

邱晨; 贾胜男; 张倩; 张传辉; 金珍婧; 杨岚岚

doi:10.3969/j.issn.1001-5256.2020.07.028

索磷布韦/维帕他韦/利巴韦林联合治疗混合基因型HCV感染者1例报告

DOI: 10.3969/j.issn.1001-5256.2020.07.028

吉林大学第二医院肝胆胰内科

基金项目:

吉林省财政厅卫生专项(3D5177893429)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 632
- HTML全文浏览量: 14
- PDF下载量: 106
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Patients with mixed genotype hepatitis C virus infection treated by sofosbuvir/velpatasvir/ribavirin: A case report

Department of Hepatobiliary and Pancreatic Medicine, The Second Hospital of Jilin University, Changchun 130022, China

Research funding:

摘要

摘要:
<正>1病例资料患者男性,65岁,因"发现HCV抗体阳性13年"于2019年3月12日就诊于本院肝胆胰内科。2005年患者体检中发现HCV抗体阳性,因肝功能、凝血功能、血常规等未见明显异常,未予治疗。2009年患者于体检时进一步检测发现HCV RNA载量4. 52×106IU/ml,丙型肝炎分型为1b亚型,肝功能等指标均正常,于当地医院进行短效IFNα100万U/次,隔日1次肌注,联合利巴韦林600 mg/d口服,疗程为48周。停药
- 肝炎病毒属 /
- 抗病毒药 /
- 基因型
- hepacivirus /
- antiviral agents /
- genotype

HTML全文

参考文献(17)

[1]MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:New estimates of agespecific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342．

[2]ZHANG Y,YAN XB.Current situation and problems of anti-hepatitis C virus therapy in era of direct-acting antiviral agents[J].World Chin J Dig,2017,25(13):1135-1142.(in Chinese)张莹，颜学兵．后DAA时代抗HCV治疗的现状及存在问题[J]．世界华人消化杂志，2017,25(13):1135-1142．

[3]ALRIC L,OLLIVIER-HOURMAND I,BRARD E,et al.Grazoprevir plus elbasvir in HCV genotype-1 or-4 infected patients with stage 4/5severe chronic kidney disease is safe and effective[J].Kidney Int,2018,94(1):206-213．

[4]FLAMM SL,BACON B,CURRY MP,et al.Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C:Retrospective analyses from the TRIO network[J].Aliment Pharmacol Ther,2018,47(11):1511-1522．

[5]HERNANDEZ-CONDE M,FERNNDEZ I,PERELLC,et al.Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection:Results from the Spanish HEPA-C real-world cohort[J].J Viral Hepat,2019,26(1):55-64．

[6] SORIA A,FAVA M,BERNASCONI DP,et al.Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort[J].Liver Int,2020,40(4):769-777．

[7] BUTT N,MUHAMMAD I,ABOU BAKR A,et al.Efficacy and safety of sofosbuvir-velpatasvir combination in hepatitis C virus-infected pakistani patients without cirrhosis or with compensated cirrhosis:Aprospective,open-label interventional trial[J].Cureus,2020,12(1):e6537．

[8] AASLD-IDSA HCV Guidance Panel.Hepatitis C guidance 2018 update:AASLD-IDSA recommendations for testing,managing,and treating hepatitis c virus infection[J].Clin Infect Dis,2018,67(10):1477-1492．

[9]HE CN,LI Y,GE H,et al.Clinical effect and safety of sofosbuvirbased regimens in treatment of hepatitis C virus-associated glomerulonephritis[J].J Clin Hepatol,2019,35(8):1714-1718.(in Chinese)贺彩妮，李彧，葛蘅，等．基于索磷布韦方案治疗HCV相关性肾小球肾炎的效果和安全性[J]．临床肝胆病杂志，2019,35(8):1714-1718．

[10]XU R,WANG M,CHEN QY,et al.The prevalence of mixed-genotype of HCV infections among chronic hepatitis C patients in China[J].Chin JViral Dis,2015,5(1):11-16.(in Chinese)许茹，王敏，陈秋宇，等．中国不同基因型/亚型丙型肝炎病毒混合感染率的研究[J]．中国病毒病杂志，2015,5(1):11-16．

[11] XIAO GR,XU T.Genotype distribution of 1998 strains of hepatitis Cvirus in west China hospital of Sichuan university from 2009 to 2013[J].J Sichuan Univ(Med Sci Edition),2016,47(5):755-758.(in Chinese)肖桂荣，徐珽．2009~2013年四川大学华西医院1998株丙型肝炎病毒基因分型研究[J]．四川大学学报(医学版)，2016,47(5):755-758．

[12]DU H,QI Y,HAO F,et al.Complex patterns of HCV epidemic in Suzhou:Evidence for dual infection and HCV recombination in East China[J].J Clin Virol,2012,54(3):207-212．

[13]FU Y,WANG Y,XIA W,et al.New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors[J].J Viral Hepat,2011,18(1):42-52．

[14] QIU P,CAI XY,DING W,et al.HCV genotyping using statistical classification approach[J].J Biomed Sci,2009,16:62．

[15]ABDELRAHMAN T,HUGHES J,MAIN J,et al.Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment[J].Hepatology,2015,61(1):88-97．

[16] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for hepatitis C(2019 version)[J].J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2670-2686．

[17] European Association for the Study of the Liver,European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol,2018,69(2):461-511.

施引文献

资源附件(0)

访问统计